|
|
|
|
|
|
||
|
|
||||
|
|
||||
|
||||
Pediatric Neuro-Oncology |
Divisions of Endocrinology (W.X., T.M.) and Neurology and Oncology (A.J., P.P.) and Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, PA 19104; Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 (J.G.); and Department of Neurology and Oncology, Children's National Medical Center, The George Washington University, Washington, DC 20010 (R.J.P.); USA
2 Address correspondence to Thomas Moshang Jr., Division of Endocrinology, The Children's Hospital of Philadelphia, 34th Street and Civic Center Boulevard, Philadelphia, PA 19104, USA (Moshang{at}email.chop.edu).
Abstract
Craniospinal radiation therapy (CSRT) combined with chemotherapy results in significant endocrine morbidity. Between 1987 and 1990, a trial using 18 Gy was conducted to treat 10 young children with medulloblastoma. There were 7 survivors. We compared the endocrine outcome in these children (group 18 Gy) to that of a comparable group treated with conventional doses of CSRT that ranged from 23 to 39 Gy (group CD). Both groups had an identical history of chemotherapy and tumor stage and were treated with recombinant growth hormone therapy (rhGH). The mean age of group 18 Gy at diagnosis was 4.0 years, and rhGH treatment was initiated in 6 children at age 9.2 years. Group CD (12 children) was diagnosed at a mean age of 5.8 years and rhGH started in 11 children at a mean age of 9.6 years. The dose of rhGH used in both groups was identical (0.3 mg/kg/wk). For group 18 Gy, adult heights and sitting heights (a mean standard deviation score of -1.01 ± 1.11 and -1.62 ± 1.16, respectively) were statistically greater (P < 0.05) than those for group CD (mean standard deviation score of -2.04 ± 0.83 and -3.16 ± 1.43, respectively). Moreover, adult heights of group 18 Gy were not different from midparental heights, unlike group CD, whose adult heights were less than midparental heights (P < 0.0001). Of other endocrine sequelae, 10 patients of the CD group were hypothyroid, 3 had adrenal insufficiency, 3 had hypogonadism, and 2 had early puberty. In contrast, within group 18 Gy, only 1 was hypothyroid (P = 0.006) and 1 had early puberty. We conclude that endocrine morbidity was significantly reduced with 18 Gy CSRT in young children with medulloblastoma.
References
Adan, L., Sainte-Rose, C., Souberbielle, J.C., Zucker, J.M., Kalifa, C., and Brauner, R. (2000) Adult height after growth hormone (GH) treatment for GH deficiency due to cranial irradiation. Med. Pediatr. Oncol. 34,14 -19.[CrossRef][Medline]
Burns, E.C., Tanner, J.M., Preece, M.A., and Cameron, N. (1981) Growth hormone treatment in children with craniopharyngioma: Final growth status. Clin. Endocrinol. 14,587 -595.[Medline]
CDC/NCHS. Centers for Disease Control, National Center for Health Statistics (2002) 2000 CDC Growth Charts: United States. Available at http://www.cdc.gov/growthcharts.
Clarson, C.L., and Del Maestro, R.F. (1999) Growth failure after treatment of pediatric brain tumors. Pediatrics 103,E37
Clayton, P.E., Shalet, S.M., Price, D.A., and Addison, G.M. (1988) Growth and growth hormone responses to oxandrolone in boys with constitutional delay of growth and puberty (CDGP). Clin. Endocrinol. 29,123 -130.[Medline]
Collet-Solberg, P.F., Sernyak, H., Satin-Smith, M., Katz, L.L., Sutton, L., Molloy, P., and Moshang, T., Jr. (1997) Endocrine outcome in long-term survivors of low-grade hypothalamic/chiasmatic glioma. Clin. Endocrinol. 47,79 -85.[CrossRef][Medline]
Costin, G. (1988) Effects of low-dose cranial radiation on growth hormone secretory dynamics and hypothalamic-pituitary function. Am. J. Dis. Child. 142,847 -852.[Abstract]
Dacou-Voutetakis, C., Kitra, V., Grafakos, S., Polychronopoulou, S., Drakopoulou, M., and Haidas, S. (1993) Auxologic data and hormonal profile in long-term survivors of childhood acute lymphoid leukemia. Am. J. Pediatr. Hematol. Oncol. 15,277 -283.[Medline]
Dangour, A.D., Schilg, S., Hulse, J.A., and Cole, T.J. (2002) Sitting height and subischial leg length centile curves for boys and girls from Southeast England. Ann. Hum. Biol. 29,290 -305.[CrossRef][Medline]
Darendeliler, F., Livesey, E.A., Hindmarsh, P.C., and Brook, C.G. (1990) Growth and growth hormone secretion in children following treatment of brain tumours with radiotherapy. Acta Paediatr. Scand. 79,950 -956.[ISI][Medline]
Goldwein, J.W., Radcliffe, J., Packer, R.J., Sutton, L.N., Lange, B., Rorke, L.B., and D'Angio, G.J. (1993) Results of a pilot study of low-dose craniospinal radiation therapy plus chemotherapy for children younger than 5 years with primitive neuroectodermal tumors. Cancer 71,2647 -2652.[CrossRef][Medline]
Goldwein, J.W., Radcliffe, J., Johnson, J., Moshang, T., Packer, R.J., Sutton, L.N., Rorke, L.B., and D'Angio, G.J. (1996). Updated results of a pilot study of low dose craniospinal irradiation plus chemotherapy for children under five with cerebellar primitive neuroectodermal tumors (medulloblastoma). Int. J. Radiat. Oncol. Biol. Phys. 34,899 -904.[CrossRef][ISI][Medline]
Helseth, E., Due-Tonnessen, B., Wesenberg, F., Lote, K., and Lundar, T. (1999) Posterior fossa medulloblastoma in children and young adults (0-19 years): Survival and performance. Childs Nerv. Syst. 15,451 -455.[CrossRef][Medline]
Kanev, P.M., Lefebvre, J.F., Mauseth, R.S., and Berger, M.S. (1991) Growth hormone deficiency following radiation therapy of primary brain tumors in children. J. Neurosurg. 74,743 -748.[CrossRef][Medline]
Kiltie, A.E., Lashford, L.S., and Gattamaneni, H.R. (1997) Survival and late effects in medulloblastoma patients treated with craniospinal irradiation under three years old. Med. Pediatr. Oncol. 28,348 -354.[CrossRef][Medline]
Leiper, A.D. (1990) Management of growth failure in the treatment of malignant disease. Pediatr. Hematol. Oncol. 7,365 -371.[Medline]
Marx, M., Schoof, E., Grabenbauer, G.G., Beck, J.D., and Doerr, H.G. (1999) Effects of puberty on bone age maturation in a girl after medulloblastoma therapy. J. Pediatr. Adolesc. Gynecol. 12,62 -66.[CrossRef][Medline]
Merchant, T.E., Goloubeva, O., Pritchard, D.L., Gaber, M.W., Xiong, X., Danish, R.K., and Lustig, R.H. (2002) Radiation dose volume effects on growth hormone secretion. Int. J. Radiat. Oncol. Biol. Phys. 52,1264 -1270.[CrossRef][Medline]
Moshang, T. (1997) Outcomes of pediatric brain tumors as related to growth and adolescent development. Curr. Opin. Endocrinol. Diabetes 4,80 -84.
Moshang, T., Jr., and Grimberg, A. (1996) The effects of irradiation and chemotherapy on growth. Endocrinol. Metab. Clin. North Am. 25,731 -741.[CrossRef][Medline]
Noorda, E.M., Somers, R., van Leeuwen, F.E., Vulsma, T., and Behrendt, H. (2001) The Dutch Late Effects Study Group. Adult height and age at menarche in childhood cancer survivors. Eur. J. Cancer 37,605 -612.
Ogilvy-Stuart, A.L., and Shalet, S.M. (1995) Growth and puberty after growth hormone treatment after irradiation for brain tumors. Arch. Dis. Child. 73,141 -146.[Abstract]
Olshan, J.S., Gubernick, J., Packer, R.J., D'Angio, D.J., Goldwein, J.W., Willi, S.M., and Moshang, T., Jr. (1992) The effects of adjuvant chemotherapy on growth in children with medulloblastoma. Cancer 70,2013 -2017.[CrossRef][ISI][Medline]
Packer, R.J., Goldwein, J., Nicholson, H.S., Vezina, L.G., Allen,
J.C., Ris, M.D., Muraszko, K., Rorke, L.B., Wara, W.M., Cohen, B.H., and
Boyett, J.M. (1999) Treatment of children with medulloblastomas
with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A
Children's Cancer Group study. J. Clin. Oncol.
17,2127
-2136.
Packer, R.J., Boyett, J.M., Janss, A.J., Stavrou, T., Kun, L.,
Wisoff, J., Russo, C., Geyer, R., Phillips, P., Kieran, M., Greenberg, M.,
Goldman, S., Hyder, D., Heideman, R., Jones-Wallace, D., August, G.P., Smith,
S.H., and Moshang, T., Jr. (2001) Growth hormone replacement
therapy in children with medulloblastoma: Use and effect on tumor control.
J. Clin. Oncol. 19,480
-487.
Probert, J.C., Lederman, M., and Bagshaw, M.A. (1973) Medulloblastoma— treatment and prognosis. A study of seventeen cases in ten years. Calif. Med. 118, 14-17.[Medline]
Ranke, M.B., and Price, D.A. (1999) Growth hormone treatment in children with malignant cranial tumors in KIGS. In: Ranke, M.B., and Wilton, P. (Eds.) Growth Hormone Therapy in KIGS: 10 Years' Experience. Heidelberg: Johann Ambrosius Barth Verlag,159 -174.
Rappaport, R., and Brauner, R. (1989) Growth and endocrine disorders secondary to cranial irradiation. Pediatr. Res. 25,561 -567[ISI][Medline]
Ricardi, U., Corrias, A., Einaudi, S., Genitori, L., Sandri, A., di Montezemolo, L.C., Besenzon, L., Madon, E., and Urgesi, A. (2001) Thyroid dysfunction as a late effect in childhood medulloblastoma: A comparison of hyperfractionated versus conventionally fractionated craniospinal radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 50,1287 -1294.[Medline]
Schmiegelow, M., Lassen, S., Poulsen, H.S., Feldt-Rasmussen, U., Schmiegelow, K., Hertz, H., and Muller, J. (2000) Cranial radiotherapy of childhood brain tumors: Growth hormone deficiency and its relation to the biological effective dose of irradiation in a large population based study. Clin. Endocrinol. 53,191 -197.[CrossRef][Medline]
Shalet, S.M. (1993) Radiation and pituitary
dysfunction. N. Engl. J. Med.
328, 131-133 (letter,
comment).
Shalet, S.M., and Brennan, B.M. (1998) Growth and growth hormone status following treatment for childhood leukaemia. Horm. Res. 50,1 -10.
Schriock, E.A., Schell, M.J., Carter, M., Hustu, O., and Ochs, J.J. (1991) Abnormal growth patterns and adult short stature in 115 long-term survivors of childhood leukemia. J. Clin. Oncol. 9,400 -405.[Abstract]
Shalet, S.M., Beardwell, C.G., Twomey, J.A., Jones, P.H., and Pearson, D. (1977) Endocrine function following the treatment of acute leukemia in childhood. J. Pediatr. 90,920 -923.[Medline]
Shalet, S.M., Gibson, B., Swindell, R., and Pearson, D. (1987) Effect of spinal irradiation on growth. Arch. Dis. Child. 62,461 -464.[Abstract]
Shalet, S.M., Crowne, E.C., Didi, M.A., Ogilvy-Stuart, A.L., and Wallace, W.H. (1992) Irradiation-induced growth failure. Baillieres Clin. Endocrinol. Metab. 6, 513-526.[CrossRef][Medline]
Sulmont, V., Brauner, R., Fontoura, M., and Rappaport, R. (1990) Response to growth hormone treatment and final height after cranial or craniospinal irradiation. Acta Paediatr. Scand. 79,542 -549.[ISI][Medline]
Thomas, P.R., Deutsch, M., Kepner, J.L., Boyett, J.M., Krischer,
J., Aronin, P., Albright, L., Allen, J.C., Packer, R.J., Linggood, R.,
Mulhern, R., Stehbens, J.A., Langston, J., Stanley, P., Duffner, P., Rorke,
L., Cherlow, J., Friedman, H.S., Finlay, J.L., Vietti, T.J., and Kun, L.E.
(2000) Low-stage medulloblastoma: Final analysis of trial
comparing standard-dose with reduced-dose neuraxis irradiation. J.
Clin. Oncol. 18,3004
-3011.
Whelan, H.T., Krouwer, H.G., Schmidt, M.H., Reichert, K.W., and Kovnar, E.H. (1998) Current therapy and new perspectives in the treatment of medulloblastoma. Pediatr. Neurol. 18,103 -115.[Medline]
This article has been cited by other articles:
|
|
 |
|
  S. J. Laughton, T. E. Merchant, C. A. Sklar, L. E. Kun, M. Fouladi, A. Broniscer, E. B. Morris, R. P. Sanders, M. J. Krasin, J. Shelso, et al. Endocrine Outcomes for Children With Embryonal Brain Tumors After Risk-Adapted Craniospinal and Conformal Primary-Site Irradiation and High-Dose Chemotherapy With Stem-Cell Rescue on the SJMB-96 Trial J. Clin. Oncol., March 1, 2008; 26(7): 1112 - 1118. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
